ArticleCancer cell2021
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.
Abstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.Advances in cancer research · 2021Pooled it
- Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer.The Journal of clinical investigation · 2026Trial
- Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.Cancer medicine · 2023Trial
- Trial
- Review
- Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Molecular biomedicine · 2026Article
- Cytoplasmic relocation of nuclear Ku70 by Bruceine A augments cGAS-STING pathway-mediated anti-tumor immunity.Acta pharmaceutica Sinica. B · 2026Article
- Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.medRxiv : the preprint server for health sciences · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- YAP1-driven tumor-like cancer-associated fibroblasts modulate biomechanics of pancreatic ductal adenocarcinoma.Journal of gastroenterology · 2026Article
- Article
- A tissue microenvironment analogous to certain tumor microenvironments facilitates HIV persistence.Frontiers in immunology · 2026Article
- Microtubule-Associated Protein 4 Overexpression Correlates with Early Recurrence in Hepatitis B Virus-Associated Hepatocellular Carcinoma Patients Following Curative Hepatic Resection.Journal of hepatocellular carcinoma · 2026Article
- The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Biomarker research · 2025Review
- Article
- A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Comparing functional and genomic-based precision medicine in blood cancer patients.HemaSphere · 2025Article
- Comprehensive whole-genome sequencing reveals origins of mutational signatures associated with aging, mismatch repair deficiency and temozolomide chemotherapy.Nucleic acids research · 2025Article
- PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.Therapeutic advances in medical oncology · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
46 authors.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Naoko TakebeDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Toshinori HinoueVan Andel Institute, Grand Rapids, MI 49503, USA.
Katherine A HoadleyDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Maria F CardenasHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Alina M HamiltonDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Peter W LairdVan Andel Institute, Grand Rapids, MI 49503, USA.
Linghua WangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Adrienne JohnsonFoundation Medicine Inc, Cambridge, MA 02141, USA.
Ninad DewalFoundation Medicine Inc, Cambridge, MA 02141, USA.
Vincent MillerFoundation Medicine Inc, Cambridge, MA 02141, USA.
David PiñeyroJosep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain.
Manuel Castro de MouraJosep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain.
Manel EstellerJosep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029 Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), 08007 Barcelona, Catalonia, Spain.
Hui ShenVan Andel Institute, Grand Rapids, MI 49503, USA.
Jean Claude ZenklusenCenter for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
Roy TarnuzzerCenter for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
Lisa M McShaneDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
James V TricoliDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Paul M WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
Irina LubenskyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Geraldine O'Sullivan-CoyneDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Elise C KohnDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Richard F LittleDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Jeffrey WhiteDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Shakun MalikDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Lyndsay HarrisDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Carol WeilDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Alice P ChenDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Chris KarlovichFrederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
Brian RodgersDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Lalitha ShankarDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Paula JacobsDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Tracy NolanDepartment of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jianhong HuHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Donna M MuznyHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Harshavardhan DoddapaneniHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Viktoriya KorchinaHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Julie Gastier-FosterNationwide Children's Hospital, Columbus, OH 43205, USA.
Jay BowenNationwide Children's Hospital, Columbus, OH 43205, USA.
Kristen LeraasNationwide Children's Hospital, Columbus, OH 43205, USA.
Elijah F EdmondsonPathology and Histology Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701, USA.
James H DoroshowDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Barbara A ConleyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
S Percy IvyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Louis M StaudtCenter for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: lstaudt@mail.nih.gov.
Funding
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MThe BCM Tumor Genome Characterization CenterU24CA143843 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A, WHEELER, DAVID ANDREW · 2009 to 2013
$9.5MPhase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0MIntegrative Cancer Epigenomic Data Analysis Center (ICE-DAC)U24CA210969 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI LAIRD, PETER W · 2016 to 2020
$2.5MRNA sequencing analysis of CancerU24CA210988 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, HOADLEY, KATHERINE A. · 2016 to 2020
$2.1MEnhancement Training for the Next Generation of Translational Ph.D. ScientistsT32GM122741 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S., YEH, JEN JEN · 2018 to 2022
$898kCCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201700005CNCI NIH HHS HHSN261201700005INCI NIH HHS U24 CA143843NCI NIH HHS U24 CA210969NCI NIH HHS U24 CA210988NIEHS NIH HHS P30 ES010126NIGMS NIH HHS T32 GM122741
Abstract
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.
Indexed as
Gene Regulatory NetworksGenetic VariationAntineoplastic AgentsBiopsyEpigenesis, GeneticFemaleGenomicsHumansMaleNeoplasmsPrognosisSurvival AnalysisTreatment OutcomeTumor MicroenvironmentAntineoplastic Agentscombination cancer therapyDNA methylation analysisDNA repair mechanismsexceptional response to therapyintegrating molecular and clinical datamulti-platform genomic analysesN of 1 experimentprecision cancer medicinerare mutationsRNA sequencingsynthetic lethalitywhole-exome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.